Pablo Parenti
机构：National University of Rosario, Instituto Cardiovascular de Rosario, Integral Consulting (United States) · ORCID：0000-0002-5882-7073
发表论文 11 篇 · 总被引 27 次 · h-index 3
代表论文
- Efficacy and Safety of Dual Therapy With Dolutegravir/Lamivudine in Treatment-naive Persons With CD4 Counts <200/mm3: 48-Week Results of the DOLCE Study (2025 · Clinical Infectious Diseases · 被引 9)
- Tenofovir-Containing Antiretroviral Therapy and Clinical Outcomes of SARS-CoV-2 Infection in People Living with HIV (2023 · Viruses · 被引 5)
- Antiretroviral therapy use in selected countries in Latin America during 2013–2017: results from the Latin American Workshop in HIV Study Group (2021 · International Journal of Infectious Diseases · 被引 4)
- Desafíos éticos y regulatorios de la Inteligencia Artificial en la investigación médica: reflexiones sobre una Regulación Inteligente (2024 · Revista Binacional Brasil-Argentina Diálogo entre as ciências · 被引 2)
- Clinical and epidemiological characteristics of the 2022-2023 Mpox outbreak in Buenos Aires, Argentina. (2025 · PubMed · 被引 1)
- Efficacy and Safety of Dual Therapy with Dolutegravir/Lamivudine in Treatment-Naive Persons with CD4 Counts <200/mm3: 48 Weeks Results of the DOLCE Study (2025 · SSRN Electronic Journal · 被引 1)